Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.DnqOsaYJ.js ...

In terms of GAAP net income attributable to Boston Scientific common stockholders, the company reported $566 million or $0.38 per share, compared to $504 million or $0.34 per share a year ago. The ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.